Pediatric lifestyle disease screening in Japan plays a crucial role in the early detection of obesity, dyslipidemia, hypertension, and type 2 diabetes. However, it is not mandated by national law, instead being conducted independently by local governments, which results in significant regional disparities. While many programs focus only on obese children, this approach risks missing high-risk individuals with normal weight, such as those with familial hypercholesterolemia (FH) or non-obese type 2 diabetes. Regional initiatives in cities such as Fukuoka, Niigata, Kumamoto, and Kitakyushu have demonstrated various effective models, including the use of growth and obesity curves, expanded screening parameters, and school–healthcare collaborations. National surveys show that fewer than 30% of municipalities conduct such screenings, often with limited standardization. Kagawa Prefecture presents a notable example of integrating FH screening with lifestyle checkups to achieve high participation and follow-up rates. To expand and improve its effectiveness, universal screening based on standardized criteria is essential. Efforts should also focus on public education, early intervention, and coordinated systems involving school nurses and teachers, pediatricians and family doctors, local medical associations, educational boards, and municipal health authorities. Universal screening, combined with individualized follow-up and strong community collaboration, can help healthcare providers, educators, and local governments in Japan respond more effectively to the growing prevalence of pediatric obesity and metabolic disorders. This approach also promotes equitable access to preventive care for children.

Patients with familial hypercholesterolemia (FH) carry an extremely elevated cardiovascular risk because of lifelong exposure to elevated low-density lipoprotein cholesterol (LDL-C). The Japan Atherosclerosis Society (JAS) complies with the clinical guidelines of FH stipulating diagnostic criteria as well as the treatment targets based on their cardiovascular preventive status. These guidelines are expected to improve the FH diagnosis rate and facilitate better LDL-C management, ultimately leading to improved patient outcomes. However, there are no clear instructions on how and when to assess atherosclerosis. In addition, current treatment target goals, especially for adults with heterozygous FH (HeFH) (LDL-C ＜100 mg/dL in primary prevention and LDL-C ＜70 mg/dL in secondary prevention), are sometimes insufficient to fully navigate to prevent cardiovascular events, given that many factors, such as hypertension, diabetes, smoking, lipoprotein (a), cholesterol-year score, coronary artery calcium, and pathogenic mutations are associated with a further increased risk on top of the LDL-C level assessed cross-sectionally. Accordingly, we summarized contemporary strategies for assessing systemic atherosclerosis and treatment options.

Aim: This study investigated the efficacy and safety of endovascular revascularization for symptomatic non-acute atherosclerotic intracranial LVO.

Methods: For non-acute atherosclerotic intracranial large vessel occlusion (LVO), despite aggressive medical treatment, recurrent ischemic stroke or transient ischemic attack related to the occluded artery still occurs repeatedly. This retrospective cohort study included stroke patients with intracranial LVO who received endovascular treatment (EVT), categorized by successful recanalization and the time interval from symptom onset to revascularization (＜30 days vs. ≥ 30 days). The primary efficacy outcome was stroke recurrence or mortality at the 6-month follow-up.

Results: Of the 264 patients in the study, 229 (87%) had successful recanalization, while 35 (13%) did not. In addition, 139 patients had recanalization times ≤ 30 days, and 125 had recanalization times ＞30 days. The successful recanalization group had a significantly lower rate of stroke recurrence or death during follow-up than the unsuccessful group (9.6% vs. 31.4%, adjusted odds ratio [OR]: 4.98, 95% confidence interval [CI]: 1.86 -13.37; P = 0.001). The group with a recanalization time ≤ 30 days also demonstrated a significantly lower rate of stroke recurrence or death during follow-up than the group with a recanalization time ＞30 days (7.9% vs.17.6%, P = 0.015). In addition, the rate of a favorable prognosis (modified Rankin Scale [mRS] 0-2) during the follow-up period was significantly higher in the successful recanalization group than in the successful recanalization group (71.1% vs. 51.4%, P = 0.021).

Conclusion: These findings suggest that successful recanalization may have therapeutic potential for patients with non-acute intracranial large-vessel occlusion, particularly for those with LVO recanalization lasting ＜30 days, who show more significant benefits than those with longer-lasting recanalization [please check this carefully].

Aims: Sex differences in the risk of venous thromboembolism (VTE) among patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) have so far only been sparsely described. This study aimed to investigate the differences in the risk of VTE events between male and female AECOPD patients and to determine whether any specific risk factors for VTE vary between the sexes.

Methods: We prospectively enrolled patients hospitalized for AECOPD from ten medical centers in China. The primary outcome was the occurrence of VTE. Univariate and multivariate logistic regression analyses were conducted to determine whether sex was an independent risk factor for VTE and also to identify any sex-specific risk factors.

Results: In total, 13,664 patients were included. VTE occurred in 5.5% of females and 3.3% of males (P＜0.001). A multivariate logistic regression analysis identified female sex as an independent risk factor for VTE in patients with AECOPD (odds ratio [OR] = 1.439, 95% confidence interval [CI] = 1.177–1.759, P＜0.001) after adjusting for confounding factors. Common risk factors for both sexes included age, chronic heart failure, severe lung disease, stroke, a recent surgical history, a history of VTE, and respiratory failure. Additional risk factors unique to males were sepsis (OR = 9.514, 95% CI = 4.513–20.056, P＜0.001), varicose veins (OR = 6.170, 95% CI = 3.237–11.763, P＜0.001), and rheumatological disorders (OR = 2.677, 95% CI = 1.184–6.052, P = 0.018). No sex-specific risk factors were identified for females.

Conclusion: Female sex was found to be an independent risk factor for VTE and some sex-specific risk factors exist among inpatients with AECOPD. These findings highlight the importance of considering sex and sex-related factors when assessing the VTE risk in AECOPD patients.

Aim: The triglyceride-glucose (TyG) index, a biomarker commonly used to evaluate metabolic health status, can predict unfavorable outcomes. Thus, we aimed to explore evidence regarding the prognostic value of the TyG index in patients with ischemic cardiomyopathy and heart failure with preserved ejection fraction (HFpEF).

Methods: We enrolled 277 consecutive participants with new-onset ischemic cardiomyopathy and HFpEF who underwent coronary artery bypass grafting (CABG). The primary study endpoint was major adverse cardiovascular events (MACEs), defined as cardiac death, acute myocardial infarction, graft failure, and stroke.

Results: During a median follow-up of 43.34 months, 70 patients (25.1%) experienced MACEs. A multivariable Cox regression analysis identified the TyG index as an independent risk factor for MACEs, with a higher baseline TyG index associated with greater risk after adjusting for confounding factors. A restricted cubic spline showed that the TyG index had a linear relationship across the range. The optimal cut-off value of 9.167 for the TyG index demonstrated a sensitivity of 70% and specificity of 84.1%, with an AUC of 0.820 (p＜0.001, 95% CI: 0.762-0.878), thus effectively stratifying participants into lower TyG index (TyG ＜9.167, n = 182) and higher TyG index groups (TyG ≥ 9.167, n = 95), while subgroup analyses confirmed a robust association with MACEs across various populations. Furthermore, the time-dependent area under the curve, calibration curve, and decision curve analyses demonstrated that incorporating the TyG index into the traditional cardiovascular risk factor model significantly enhanced the prediction of MACE risk. Additionally, significant net reclassification improvement (0.335, 95% confidence interval [CI]: 0.136-0.518, p＜0.05) and integrated discrimination improvement (0.178, 95%CI: 0.089-0.270, p＜0.001) were also observed.

Conclusion: The TyG index is a reliable prognostic indicator for MACEs after CABG in patients with ischemic cardiomyopathy and HFpEF and it serves as a valuable complement to traditional cardiovascular risk factors by providing metabolic-related insights.

Aim: To compare the effectiveness and safety of moderate-intensity pravastatin 40 mg/day and atorvastatin 10 mg/day in patients with dyslipidemia.

Methods: We conducted a retrospective cohort study using electronic health records of 19 million patients across 14 secondary/tertiary hospitals, standardized to a Common Data Model. New users of pravastatin (40 mg/day) and atorvastatin (10 mg/day) were identified. Six distinct cohorts were used to assess the comparative effectiveness in preventing major adverse cardiovascular events (MACE) and the risks of new-onset diabetes mellitus (NODM), myalgia or rhabdomyolysis, and hepatotoxicity (measured by aspartate aminotransferase [AST]/alanine aminotransferase [ALT]). Propensity score matching (PSM) was applied to each cohort for effectiveness and safety analyses, followed by a meta-analysis of hospital-specific results.

Results: After PSM, patients were equally assigned to the pravastatin and atorvastatin groups for primary (n = 2,688/group) and secondary MACE prevention (n = 1,258/group) and to assess the risk of NODM (n = 2,391/group), new-onset myalgia or rhabdomyolysis (n = 11,799/group), and hepatotoxicity (AST, n = 4,034/group; ALT, n = 3,655/group). No significant differences were observed in the hazard ratios (HRs) for primary (HR = 0.84; 95% CI, 0.59-1.20) and secondary MACE prevention (HR = 0.89; 95% CI, 0.68-1.16). Similarly, no significant difference was observed in the risk of NODM (HR, 0.99; 95% CI, 0.79-1.23). The risk of new-onset myalgia/rhabdomyolysis (HR = 0.82, 95% CI, 0.69-0.96) and the incidence of abnormal elevations in AST levels (2.35% vs. 3.37%, p＜0.05) were significantly lower in the pravastatin group.

Conclusion: Moderate-intensity pravastatin (40 mg/day) showed comparable effectiveness to moderate-intensity atorvastatin (10 mg/day) in preventing MACE with a more favorable safety profile.

Aim: We investigated the association of obesity and metabolic health status with cerebral small-vessel disease (SVD), a predictor of stroke, in stroke-free participants during brain health checkups.

Methods: An observational cross-sectional study was conducted on 6,088 stroke-free participants who underwent brain magnetic resonance imaging (MRI). Abdominal obesity was defined as a waist circumference ≥ 90 cm for men and ≥ 80 cm for women. A metabolically healthy status was defined as having none of the three components of metabolic syndrome, except abdominal obesity. The total SVD scores were derived from four MRI markers: silent lacunar infarcts, cerebral microbleeds, moderate-to-severe white-matter hyperintensity, and enlarged perivascular spaces.

Results: The mean age of participants was 55±12 years old. Obesity was prevalent in 50% of the patients. The prevalence of a total SVD score ≥ 2 (moderate-to-severe SVD) was 348 (6%), which was elevated in metabolically unhealthy individuals regardless of obesity status. Compared with the metabolically healthy non-obese group, the metabolically unhealthy non-obese (odds ratio [OR] 2.08, [95% confidence interval {CI}, 1.33–3.27]) and metabolically unhealthy obese (OR 2.62, [95% CI, 1.70–4.04]) groups had a higher multivariable-adjusted risk for a total SVD score ≥ 2. Similar results were obtained for obesity defined as a body mass index ≥ 25 kg/m² instead of abdominal obesity.

Conclusions: Abdominal and general obesity alone were not associated with high total SVD scores in stroke-free individuals. Metabolically unhealthy status, especially high blood pressure and hyperglycemia, are significant risk factors for moderate-to-severe SVD.

Aim: To explore the prognostic value of the first 24-h urine output (UO) after admission in patients with acute pulmonary embolism (APE) in the intensive-care unit (ICU) for short- and long-term all-cause mortality risk.

Methods: This retrospective cohort study used the MIMIC-IV database. Patients with APE were divided into 4 teams (T1–T4) by their first 24-h UO after admission: T1 (UO ≤ 400 ml), T2 (400＜UO ≤ 800 ml ), T3 (800＜UO ≤ 2500 ml), and T4 (UO＞2500 ml). The primary endpoints were the three-month and one-year all-cause mortality rates. The relationship between UO and mortality was assessed using Kaplan-Meier survival curves and Cox proportional hazards models.

Results: This study included 2012 patients with APE, of whom 50.75% were female. Compared to the T3 group, patients in the T1 and T2 groups had higher all-cause mortality rates. Kaplan-Meier survival curves showed that patients in the T1 and T2 groups had a higher risk of death, while those in the T4 group seemed to have a lower risk of death (P＜0.001). The results remained stable in all three adjusted models and subgroup analyses. A restricted cubic spline analysis (RCS) revealed that the risk of all-cause mortality gradually decreased with an increase in UO, showing an “L”-shaped relationship. A UO of ＜1283 ml increased the risk of death in patients. Subgroup analysis indicated that the first 24-h UO was associated with 3-month and 1-year all-cause mortality rates in most subgroups of patients.

Conclusions: The first 24-h UO after admission is an important indicator for the prognosis of APE patients. A lower 24-h UO is strongly related to a higher risk of short-term and long-term all-cause mortality in ICU patients with APE.

Aim: Sedentary behavior and physical inactivity increase the risk of cardiometabolic diseases. It is important to evaluate physical activity in daily life and understand the influence of these factors on cardiometabolic diseases in the Japanese population, which tends to have a prolonged sitting time. We examined the association between sedentary behavior and physical inactivity, characterized by extended television (TV) viewing and low step counts, which are easily monitored and modifiable, and cardiometabolic risk factors in the Japanese population.

Methods: This cross-sectional study included 2,531 Japanese adults (1,087 men and 1,444 women) 20–91 years old, randomly selected throughout Japan. TV viewing was assessed using a self-reported questionnaire, and step counts were measured using pedometers. Cardiometabolic risk factors were determined using physical examinations or blood samples. The association between sedentary behavior and physical inactivity with each risk factor was examined using a cross-sectional analysis with multivariate-adjusted logistic regression models.

Results: In both sexes, longer TV viewing positively correlated with low high-density lipoprotein (HDL) cholesterol and high triglycerides (TG). In women, TV viewing time is associated with obesity and increased abdominal circumference (AC). Conversely, in men, lower step counts were positively associated with obesity and increased AC, low HDL cholesterol, and high TG levels.

Conclusions: The association between prolonged TV viewing and cardiometabolic risk factors was more pronounced in women than in men, whereas the influence of lower step counts was stronger in men than in women. These findings contribute to the improvement of cardiovascular health by monitoring and managing individual screen times and step counts in daily life.

Aims: The safety and efficacy of drug-coated balloon angioplasty (DCBA), compared to plain old balloon angioplasty (POBA) for peripheral artery in-stent restenosis (ISR), have been examined in clinical trials. However, little is known about the pathological response after DCBA for ISR. We compared the intravascular imaging findings and tissue responses of in-stent neointima in iliac arteries after DCBA and POBA using atherosclerotic porcine peripheral arteries.

Methods: Bare metal stents (BMSs) were implanted in the iliac arteries of microminipigs fed high-cholesterol chow. Four weeks after BMS implantation, stented regions were assessed by optical coherence tomography (OCT), followed by either DCBA or POBA. The adherence of the drugs delivered was observed by OCT and angioscopy, performed immediately after DCBA, and then confirmed with scanning electron microscopy. Four weeks after balloon angioplasty, the stented regions were investigated by OCT followed by pathological examination.

Results: Neointimal volume after DCBA was significantly reduced, while that after POBA showed minimal change. Histological assessments revealed decreases in cell number and the α-smooth muscle actin (SMA)-positive area, while the aniline blue-positive area and the alcian blue-positive area in the neointima was increased, after DCBA as compared to after POBA.

Conclusions: The neointima after DCBA in the BMS-implanted region showed fewer smooth muscle cells and more mature extracellular matrix than that after POBA. These results confirmed the clinical benefits of DCBA with ISR for lower extremity arterial disease.